Healthcare

Healthcare

CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

February 14, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Reports Continued Positive Clinical Data on its Phase 1b/2 mTNBC and Expanded Access Studies for MBC Ahead of Breakthrough Therapy Designation Decision From the FDA

VANCOUVER, Washington, Feb. 14, 2020 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today continued positive […]

Healthcare

CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on February 6, 2020

February 4, 2020 admin Comments Off on CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on February 6, 2020

VANCOUVER, Washington, Feb. 03, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Healthcare

CytoDyn (OTC: CYDY) Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition

January 31, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Announces Stunning Results from Clinical Trials Evaluating mTNBC and MBC with Leronlimab and will Request an Emergency Type C Meeting with FDA to Enroll 50 Awaiting Patients with a Serious Solid Tumor Cancer Condition

Third patient data supports leronlimab (PRO 140) as a potential treatment option for metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). Patient CTC dropped to zero after 2 weeks of leronlimab treatment, same […]

Healthcare

CytoDyn’s (OTC: CYDY) Leronlimab Under Evaluation for Potential Treatment of Coronavirus

January 28, 2020 admin Comments Off on CytoDyn’s (OTC: CYDY) Leronlimab Under Evaluation for Potential Treatment of Coronavirus

CytoDyn and IncellDX in discussions with potential partners about the use of leronlimab to treat 2019 Novel Coronavirus (2019-nCoV) VANCOUVER, Washington, Jan. 28, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology […]

Healthcare

CytoDyn (OTC: CYDY) Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure

January 27, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Abstract by Dr. Jonah Sacha for Use of Leronlimab as PrEP is Accepted by the Keystone Symposia on HIV Pathogenesis and Cure

VANCOUVER, Washington, Jan 27, 2020 — The poster and oral presentation will highlight the role of the CCR5 antibody in preventing macaques from intrarectal Simian-Human Immunodeficiency Virus (SHIV) Based on these strong results, CytoDyn has […]

Healthcare

Impressive Results Continue from CytoDyn’s (OTC: CYDY) Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC

January 22, 2020 admin Comments Off on Impressive Results Continue from CytoDyn’s (OTC: CYDY) Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC

VANCOUVER, Washington, Jan 22, 2020 — First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab […]

Healthcare

CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

January 13, 2020 admin Comments Off on CytoDyn (OTC: CYDY) Files for Breakthrough Therapy Designation with the FDA for the Use of Leronlimab for the Treatment of Metastatic Triple-Negative Breast Cancer

VANCOUVER, Washington, Jan. 13, 2020  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that the […]

Healthcare

CytoDyn (OTC: CYDY) Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials

December 23, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Reports Early, But Strong Positive Clinical Responses for Two Patients, One in Metastatic Breast Cancer and One in Metastatic Triple-Negative Breast Cancer Trials

Objective clinical responses in these two patients treated with leronlimab (PRO 140) lead to plans for imminent filing of a Breakthrough Therapy Designation Application while trial enrollment efforts continue at much higher pace VANCOUVER, Washington, […]

Healthcare

CytoDyn (OTC: CYDY) Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

December 17, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Signs Definitive Agreements with Vyera Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

VANCOUVER, Washington and NEW YORK, Dec 17, 2019 – In exchange for the exclusive right to market and distribute leronlimab in the U.S. for HIV-related indications, Vyera will pay upfront and regulatory and sales-based milestone […]

Healthcare

CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on December 17, 2019

December 12, 2019 admin Comments Off on CytoDyn (OTC: CYDY) to Hold Investment Community Conference Call on December 17, 2019

VANCOUVER, Washington, Dec. 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Nader […]

Healthcare

CytoDyn (OTC: CYDY) Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

December 3, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

VANCOUVER, Washington, Dec 03, 2019  — First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 […]